247 related articles for article (PubMed ID: 17187139)
21. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Jost WH; Kohl A
J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
[TBL] [Abstract][Full Text] [Related]
22. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
[TBL] [Abstract][Full Text] [Related]
23. Pain relief in patients receiving periocular botulinum toxin A.
Harrison AR; Erickson JP; Anderson JS; Lee MS
Ophthalmic Plast Reconstr Surg; 2008; 24(2):113-6. PubMed ID: 18356715
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Wu CJ; Shen JH; Chen Y; Lian YJ
Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
[TBL] [Abstract][Full Text] [Related]
25. A double-blind, randomized, crossover study of prosigne versus botox in patients with blepharospasm and hemifacial spasm.
Rieder CR; Schestatsky P; Socal MP; Monte TL; Fricke D; Costa J; Picon PD
Clin Neuropharmacol; 2007; 30(1):39-42. PubMed ID: 17272968
[TBL] [Abstract][Full Text] [Related]
26. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
Lolekha P; Choolam A; Kulkantrakorn K
Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
[TBL] [Abstract][Full Text] [Related]
27. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
[TBL] [Abstract][Full Text] [Related]
28. The effect of botulinum toxin a treatment on tear function parameters and on the ocular surface.
Horwath-Winter J; Berglöff J; Flögel I; Haller-Schober EM; Müllner K; Schmut O
Adv Exp Med Biol; 2002; 506(Pt B):1241-6. PubMed ID: 12614060
[No Abstract] [Full Text] [Related]
29. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
Sacramento DRC; Lima A; Maia DP; Cunningham M; Maciel RH; Camargos ST; Cardoso F
Mov Disord; 2019 Sep; 34(9):1401-1403. PubMed ID: 31251420
[No Abstract] [Full Text] [Related]
30. Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.
Poonyathalang A; Preechawat P; Jamnansiri U
Jpn J Ophthalmol; 2005; 49(4):327-8. PubMed ID: 16075337
[No Abstract] [Full Text] [Related]
31. [Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].
Winterhoff J; Laskawi R
HNO; 2012 Jun; 60(6):479-83. PubMed ID: 22669435
[TBL] [Abstract][Full Text] [Related]
32. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm.
Kenney C; Jankovic J
J Neural Transm (Vienna); 2008; 115(4):585-91. PubMed ID: 17558461
[TBL] [Abstract][Full Text] [Related]
33. Lid wiper epitheliopathy in patients with blepharospasm and/or hemifacial spasm.
Romero-Caballero MD; Salmerón Ato MP; Palazón-Cabanes A; Caravaca-Alegría A
Arch Soc Esp Oftalmol (Engl Ed); 2022 Jul; 97(7):376-380. PubMed ID: 35292220
[TBL] [Abstract][Full Text] [Related]
34. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
[TBL] [Abstract][Full Text] [Related]
35. Botulinum toxin type B in blepharospasm and hemifacial spasm.
Colosimo C; Chianese M; Giovannelli M; Contarino MF; Bentivoglio AR
J Neurol Neurosurg Psychiatry; 2003 May; 74(5):687. PubMed ID: 12700325
[No Abstract] [Full Text] [Related]
36. Five-Year Retrospective Review of Cases with Benign Essential Blepharospasm and Hemifacial Spasm Presenting in a Tertiary Eye Care Center in North India.
Raj A; Arya SK; Deswal J; Bamotra RK
Semin Ophthalmol; 2017; 32(3):371-376. PubMed ID: 27078720
[TBL] [Abstract][Full Text] [Related]
37. Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm.
Snir M; Weinberger D; Bourla D; Kristal-Shalit O; Dotan G; Axer-Siegel R
Am J Ophthalmol; 2003 Jul; 136(1):99-105. PubMed ID: 12834676
[TBL] [Abstract][Full Text] [Related]
38. Outcome of Injection Botulinum Toxin in Blepharospasm.
Amatya M; Limbu B; Sthapit PR; Gurung HB; Saiju R
Nepal J Ophthalmol; 2021 Jan; 13(25):40-49. PubMed ID: 33981096
[TBL] [Abstract][Full Text] [Related]
39. A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial.
Lawes-Wickwar S; McBain H; Brini S; Hirani SP; Hurt CS; Flood C; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
BMC Neurol; 2022 Mar; 22(1):99. PubMed ID: 35300599
[TBL] [Abstract][Full Text] [Related]
40. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
Grosset DG; Tyrrell EG; Grosset KA
J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
